Publications by authors named "James Nugteren"
Article Synopsis
- Ipatasertib (GDC-0068) is a targeted cancer treatment being developed by Genentech/Roche, focusing on inhibiting the Akt protein kinase, with studies examining its effects both alone and with other therapies.
- An open-label study with radiolabeled ipatasertib assessed how the drug is absorbed, metabolized, and excreted, showing a bioavailability of 34.0% and similar terminal half-lives for oral and intravenous forms.
- The majority of the drug recovered was metabolized, primarily through hepatic pathways, with the main metabolic process being -dealkylation facilitated by the CYP3A enzyme.
Background: TAS-102 is an oral fluoropyrimidine prodrug composed of trifluridine (FTD) and tipiracil hydrochloride (TPI) in a 1:0.5 ratio. FTD is a thymidine analog, and it is degraded by thymidine phosphorylase (TP) to the inactive trifluoromethyluracil (FTY) metabolite.
View Article and Find Full Text PDF